<DOC>
	<DOCNO>NCT00005608</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness fluorouracil-uracil leucovorin treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Fluorouracil-Uracil Leucovorin Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate woman metastatic breast cancer treat fluorouracil-uracil leucovorin calcium first line therapy . II . Determine time disease progression patient population treat regimen . III . Evaluate toxicity profile regimen patient . OUTLINE : Patients receive oral fluorouracil-uracil oral leucovorin calcium twice daily 28 day follow 1 week rest . Treatment continue minimum 2 course absence unacceptable toxicity disease progression . Patients respond disease receive minimum 6 course treatment . Patients follow survival . PROJECTED ACCRUAL : A total 22-33 patient accrue study within 13-14 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Metastatic breast cancer Bidimensionally measurable evaluable disease No bone metastases site measurable evaluable disease receive bisphosphonate therapy le 2 month No know evidence brain metastasis , lymphangitis lung metastasis , carcinomatous meningitis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST ALT great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Calcium great 1.3 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history cancer except curatively treat carcinoma situ cervix nonmelanomatous skin cancer No active serious infection serious underlie medical condition would preclude study therapy No dementia significantly alter mental status would preclude study consent No known hypersensitivity fluorouraciluracil leucovorin calcium PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Concurrent colony stimulate factor ( e.g. , filgrastim ( GCSF ) , sargramostim ( GMCSF ) ) allow time treatment course Chemotherapy : No prior chemotherapy metastatic disease At least 6 month since prior adjuvant chemotherapy recover Prior adjuvant fluorouracil allow provide infusional No prior fluorouraciluracil without leucovorin calcium , capecitabine , S1 , ethynyl uracil No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy metastatic disease adjuvant setting allow Recovered toxicity No concurrent hormonal anticancer therapy Radiotherapy : Prior radiotherapy metastatic disease adjuvant setting allow At least 2 week since prior radiotherapy recover No prior radiotherapy great 30 % bone marrow No concurrent radiotherapy except palliation painful bone metastasis , pathologic fracture know lytic disease , brain lesion develop Surgery : Not specify Other : No concurrent investigational therapy No concurrent anticancer drug No concurrent halogenated antiviral agent ( e.g. , lodenosine , fialuridine , LFMAU , emtricitabine , sorivudine ) No concurrent initiation bisphosphonate therapy development new bone lesion progression exist bone lesion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>